India, Dec. 22 -- image credit- freepik

Indore-based Symbiotec Pharmalab,a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables,hasfiled its Draft Red Herring Prospectus(DRHP)with market regulator Securities and Exchange Board of India(SEBI).

The company plans to raise funds through offer of equity shares (face value Rs 2each)throughinitial public offerings aggregating up to Rs2,180 crore. The offer comprises of fresh issue of equityshares aggregating up to Rs150crore(The Fresh Issue) and offer for sale by Selling Shareholdersaggregating up to Rs2,030 crore(TheOffer for Sale).

The company plans to utilis...